Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$423.33 USD

423.33
206,725

+5.48 (1.31%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $424.08 +0.75 (0.18%) 7:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.

    Zacks Equity Research

    QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2

    by Zacks Equity Research

    QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.

      Zacks Equity Research

      Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance

      by Zacks Equity Research

      Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.

        Zacks Equity Research

        Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues

        by Zacks Equity Research

        Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.

          Zacks Equity Research

          DVA vs. CHE: Which Stock Should Value Investors Buy Now?

          by Zacks Equity Research

          DVA vs. CHE: Which Stock Is the Better Value Option?

            Zacks Equity Research

            Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised

            by Zacks Equity Research

            Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.

              Zacks Equity Research

              Outpatient & Home Healthcare Stock Outlook: Prospects Bright

              by Zacks Equity Research

              The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.

                Nabaparna Bhattacharya headshot

                Outpatient Market Gains on Social Awareness: 3 Stocks in Focus

                by Nabaparna Bhattacharya

                Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.

                  Zacks Equity Research

                  LHCG or CHE: Which Is the Better Value Stock Right Now?

                  by Zacks Equity Research

                  LHCG vs. CHE: Which Stock Is the Better Value Option?

                    Zacks Equity Research

                    Walgreens Boots' Retail Pharmacy Strong Despite Several Woes

                    by Zacks Equity Research

                    Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.

                      Zacks Equity Research

                      Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                      by Zacks Equity Research

                      Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.

                        Tirthankar Chakraborty headshot

                        New Strong Buy Stocks for June 18th

                        by Tirthankar Chakraborty

                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                          Zacks Equity Research

                          LHCG or CHE: Which Is the Better Value Stock Right Now?

                          by Zacks Equity Research

                          LHCG vs. CHE: Which Stock Is the Better Value Option?

                            Zacks Equity Research

                            Envision Healthcare's (EVHC) Ratings on Review for Downgrade

                            by Zacks Equity Research

                            Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.

                              Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters

                                John Blank headshot

                                The World Cup Begins: Global Week Ahead

                                by John Blank

                                We have lots of global events this week, counted in terms of soccer games, a historic diplomatic summit, and three major monetary policy meetings.

                                  Zacks Equity Research

                                  Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates

                                  by Zacks Equity Research

                                  Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.

                                    Zacks Equity Research

                                    LHCG or CHE: Which Is the Better Value Stock Right Now?

                                    by Zacks Equity Research

                                    LHCG vs. CHE: Which Stock Is the Better Value Option?

                                      Zacks Equity Research

                                      Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?

                                      by Zacks Equity Research

                                      Style Box ETF report for VIOG

                                        Zacks Equity Research

                                        Why Is Chemed (CHE) Up 13.6% Since Its Last Earnings Report?

                                        by Zacks Equity Research

                                        Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Zacks Equity Research

                                          Amedisys or Chemed: Which is a Better Investment Choice?

                                          by Zacks Equity Research

                                          After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                                            Zacks Equity Research

                                            Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why

                                            by Zacks Equity Research

                                            Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.

                                              Zacks Equity Research

                                              BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat

                                              by Zacks Equity Research

                                              BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.

                                                Zacks Equity Research

                                                STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y

                                                by Zacks Equity Research

                                                Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.

                                                  Zacks Equity Research

                                                  Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact

                                                  by Zacks Equity Research

                                                  We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.